This Market Spotlight report covers the Acute Decompensated Heart Failure (ADHF) market, comprising key marketed and pipeline drugs, upcoming events, clinical trials, probability of success, and epidemiology information.
Key Takeaways Approved drugs in the acute decompensated heart failure (ADHF) space target natriuretic peptide receptors, phosphodiesterase 3, potassium channels, and troponin-C. All of the approved therapies are administered via the intravenous route, with two drugs also being available in an oral formulation.
The greatest proportion of industry-sponsored drugs in active clinical development for ADHF are in Phase I. Therapies in development for ADHF focus on targets such as Na-K-Cl cotransporter, guanylate cyclase, ryanodine receptor, sarcoplasmic reticulum Ca2+-ATPase, troponin, beta-3 adrenergic receptor, vasopressin receptors, and relaxin family peptide receptors 1–4. These therapies are administered via the oral, intravenous, and subcutaneous routes.
High-impact upcoming events for drugs in the ADHF space comprise topline Phase II trial results for istaroxime, topline Phase IIa trial results for APD418, and topline Phase IIb trial results for cimlanod.
The overall likelihood of approval of a Phase I ADHF asset is 1.6%, and the average probability a drug advances from Phase III is 28.6%. Drugs, on average, take 12.9 years from Phase I to approval, compared to 10.1 years in the overall cardiovascular space.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for ADHF have been in the late phases of development, with 58% of trials in Phase III–IV, and 42% in Phase I–II.
Clinical trial activity in the ADHF space is dominated by completed trials. Johnson and Johnson has the highest number of completed clinical trials for ADHF, with 17 trials.
Johnson and Johnson leads industry sponsors with the highest overall number of clinical trials for ADHF, followed by Novartis
Our reports have been used by over 10K customers, including:
Atherosclerosis (Cardiovascular) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Drugs In Development, 2021, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.Atherosclerosis (or arteriosclerotic...
Hypertrophic Cardiomyopathy (Cardiovascular) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Hypertrophic Cardiomyopathy - Drugs In Development, 2021, provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape.Hypertrophic...
Deep Vein Thrombosis (DVT) (Cardiovascular) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Deep Vein Thrombosis - Drugs In Development, 2021, provides an overview of the Deep Vein Thrombosis (Cardiovascular) pipeline landscape. Deep venous...
Cholesteryl Ester Transfer Protein - Drugs In Development, 2021 Summary According to the recently published report ’Cholesteryl Ester Transfer Protein - Drugs In Development, 2021’; Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 6 molecules....
Myocarditis (Cardiovascular) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis (Cardiovascular) - Drugs In Development, 2021, provides an overview of the Myocarditis (Cardiovascular) pipeline landscape. Myocarditis is inflammation...
The analyst presents post–COVID-19 growth opportunities and strategic imperatives for the global decentralized clinical trials (DCT) market, covering the market’s maturity, key participants, adoption drivers and restraints, and recent mergers and acquisitions. The report identifies initiatives by major global contract research organizations...
The ePRO, ePatient diaries, and eCOA market in Asia Pacific is expected to grow from US$ 348.8 million in 2021 to US$ 964.2 million by 2028; it is estimated to grow at a CAGR of 15.6% from 2021 to 2028. Healthcare systems are experiencing a rise in consumer engagement worldwide. In developing countries, health care systems are becoming more...
Health Provider Density
Medical Technology Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.